Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report sent to investors on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price target on shares of Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a report on Wednesday, August 7th.

Minerva Neurosciences Stock Performance

Shares of NERV stock opened at $2.95 on Friday. The firm’s 50 day moving average price is $2.92 and its two-hundred day moving average price is $2.79. The stock has a market cap of $20.62 million, a PE ratio of -0.66 and a beta of 0.14. Minerva Neurosciences has a 52-week low of $2.26 and a 52-week high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, sell-side analysts predict that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.